A carregar...
Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future
Molecularly targeted agents are changing the therapeutic landscape in advanced non-small cell lung cancer. Since the discovery of sensitizing mutations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) domain, clinical investigations have focused on optimizing the e...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4145253/ https://ncbi.nlm.nih.gov/pubmed/25221748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2014.00233 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|